A Novel Approach to Prevent Surgical Diabetes in Chronic Pancreatitis Patients
预防慢性胰腺炎患者手术糖尿病的新方法
基本信息
- 批准号:8788520
- 负责人:
- 金额:$ 18.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-01 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAllogenicAllograftingAnimal ModelApoptosisAutologous TransplantationBeta CellBiometryCarbon MonoxideCell SurvivalCell physiologyCellsClinicalClinical NursingClinical ResearchClinical TrialsComplexCyclic GMPDataDiabetes MellitusDoseDouble-Blind MethodEnrollmentEnsureEnvironmentExposure toFunctional disorderFundingGlucoseGoalsGrantHarvestHealthHomologous TransplantationHumanHypoxiaImmuneInfusion proceduresInjuryInsulinInsulin-Dependent Diabetes MellitusIntractable PainIslet CellIslets of Langerhans TransplantationKidney TransplantationMeasuresMethodsModelingNon-Insulin-Dependent Diabetes MellitusNutrientOperative Surgical ProceduresPPAR gammaPancreasPancreatectomyPatientsPeptidesPhase II Clinical TrialsProceduresProtocols documentationQuality of lifeRandomizedReactive Oxygen SpeciesRecruitment ActivityResearchRestSolutionsStressSurgical ManagementTestingTimeTotal PancreatectomyTranslatingTransplantationUnited Statesarmbasebench to bedsidechronic pancreatitiscytokinedeprivationexperienceglycemic controlimplantationimprovedisletmeetingsnovelnovel strategiespreventresponsestressor
项目摘要
DESCRIPTION (provided by applicant): Total pancreatectomy and islet autotransplantation (IAT) is safe and effective in the management of intractable pain associated with chronic pancreatitis. A major problem associated with IAT is that the number of islets available for transplant is compromised by a severely diseased and fibrotic pancreas. Moreover, as many as 50-60% of islet cells undergo apoptosis at 2-3 days after intraportal transplantation when transplantation associated stressors (hypoxia, nutrient deprivation, reactive oxygen species, proinflammation cytokines) are induced during harvesting, isolation, and implantation of the islet cell mass. Although the quality-of-life parameters are significantly improved in our IAT patients, only 25% of patients become insulin independent (compared to 80% patients with normoglycemia before pancreatectomy). Strategies that produce more "robust" islets to resist stressors that induce ß cell apoptosis are an appealing and promising method to improve the efficiency of human IAT. Over the past 10 years we have focused on exploring strategies that can improve islet/ß cell survival and function to treat patient with type-1 diabetes in the settingof allogeneic transplantation. Our novel findings indicate that exposing islets to low doses of carbon monoxide (CO, gaseous or dissolved in solutions) to the islet donor, or isolated islets, can protect those islets from stress-induced apoptosis and immune rejection after transplantation. Further study indicates that CO exposure to islet donor up-regulates expression of PPARγ, a transcriptional factor, in isolated islets. Donor treatment with PPARγ agonists leads to long-term (>100 days) survival of transplanted islets in a major mismatch islet transplantation
model without any additional treatments. Islet autografts suffer from similar injuries as allograft
and are spared the additional complexities of immune rejection response after transplantation. Thus, strategies such as PPARγ activation and CO exposure that can protect human islets from stress will bring immediate benefit to patients with chronic pancreatitis receiving an IAT and potentially serve as a platform on which to address the more complex allogeneic islet cell transplantation. In this study, we will test the hypothesis that stress-induced apoptosis of post IAT islets can be minimized leading to increased survival and function by harvesting islets in a CO-rich environment and/or PPARγ induction is isolated islets. Our state-of-the-art cGMP facility that undertakes IAT on a regular basis, our strong clinical and research team, clinical tral support, clinical trial nursing, clinical facilities, current patient pool and the biostatistics suport at MUSC offers powerful platform that can readily translate research finding from bench to bedside. Once the study is completed, it promises to advance the field of islet transplantation forward.
描述(申请人提供):全胰腺切除和自体胰岛移植(IAT)在治疗慢性胰腺炎相关的顽固性疼痛方面是安全和有效的。与IAT相关的一个主要问题是,可供移植的胰岛数量受到严重病变和纤维化的胰腺的影响。此外,多达50-60%的胰岛细胞在门脉内移植后2-3天发生凋亡,在胰岛细胞团的采集、分离和植入过程中,由于移植相关应激因素(缺氧、营养剥夺、活性氧、促炎细胞因子)的诱导,胰岛细胞发生了凋亡。尽管我们的IAT患者的生活质量参数得到了显著改善,但只有25%的患者实现了胰岛素非依赖性(与之相比,胰腺切除术前80%的患者血糖正常)。产生更多“健壮”的胰岛以抵抗诱导细胞凋亡的应激源的策略是提高人类IAT效率的一种有吸引力的和有前途的方法。在过去的10年里,我们一直致力于在同种异体移植的背景下,探索能够改善胰岛细胞存活和功能的策略来治疗1型糖尿病患者。我们的新发现表明,将胰岛暴露于低剂量的一氧化碳(CO,气体或溶解在溶液中)给胰岛供体,或分离的胰岛,可以保护这些胰岛免受应激诱导的细胞凋亡和移植后的免疫排斥反应。进一步研究表明,CO暴露于胰岛供体可上调胰岛中转录因子PPARγ的表达。供者使用PPARγ激动剂治疗大失配胰岛移植可使移植胰岛长期存活(100天)
无需任何额外处理的模型。自体胰岛移植物与同种异体胰岛移植物的损伤相似。
并避免了移植后免疫排斥反应的额外复杂性。因此,诸如PPARγ激活和CO暴露等可以保护人类胰岛免受应激的策略将为接受IAT的慢性胰腺炎患者带来直接好处,并可能成为解决更复杂的同种异体胰岛细胞移植的平台。在这项研究中,我们将检验这样一种假设,即在富含CO的环境中采集胰岛和/或PPARγ诱导的孤立胰岛可以最大限度地减少应激诱导的胰岛凋亡,从而提高存活和功能。我们最先进的cGMP设施定期进行IAT,我们强大的临床和研究团队、临床试验支持、临床试验护理、临床设施、现有患者池和MUSC的生物统计支持提供了强大的平台,可以轻松地将研究成果从工作台转换到床边。一旦研究完成,有望推动胰岛移植领域的发展。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ Levels.
- DOI:10.1038/srep09886
- 发表时间:2015-05-28
- 期刊:
- 影响因子:4.6
- 作者:Liu J;Dong H;Zhang Y;Cao M;Song L;Pan Q;Bulmer A;Adams DB;Dong X;Wang H
- 通讯作者:Wang H
Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function.
来自慢性胰腺炎患者的脂肪干细胞可改善小鼠和人类胰岛的存活和功能。
- DOI:10.1186/s13287-017-0627-x
- 发表时间:2017
- 期刊:
- 影响因子:7.5
- 作者:Song,Lili;Sun,Zhen;Kim,Do-Sung;Gou,Wenyu;Strange,Charlie;Dong,Huansheng;Cui,Wanxing;Gilkeson,Gary;Morgan,KatherineA;Adams,DavidB;Wang,Hongjun
- 通讯作者:Wang,Hongjun
Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice.
- DOI:10.1186/s13287-015-0201-3
- 发表时间:2015-10-31
- 期刊:
- 影响因子:7.5
- 作者:Cao M;Pan Q;Dong H;Yuan X;Li Y;Sun Z;Dong X;Wang H
- 通讯作者:Wang H
Oxidative Stress in Pancreatic Beta Cell Regeneration.
- DOI:10.1155/2017/1930261
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:Wang J;Wang H
- 通讯作者:Wang H
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hongjun Wang其他文献
Hongjun Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hongjun Wang', 18)}}的其他基金
Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Chronic Pancreatitis and Its Associated Pain
间充质干细胞治疗慢性胰腺炎及其相关疼痛的安全性和有效性
- 批准号:
10721284 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10474572 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10315988 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10640946 - 财政年份:2021
- 资助金额:
$ 18.69万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10292900 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10044402 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10515305 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10599910 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10376342 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Micro- and nanofiber enabled biomimetic periosteum for bone repair and reconstruction
微米和纳米纤维仿生骨膜用于骨修复和重建
- 批准号:
9026932 - 财政年份:2016
- 资助金额:
$ 18.69万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)